Document Type

Abstract

Publication Date

2-11-2026

Academic Year

2025-2026

Comments

Presented at the 2026 Scholarly Inquiry (SI) Research Project Symposium.

Abstract

Background: Meningiomas are the most common primary intracranial tumors. WHO Grade I meningiomas are considered benign and demonstrate high radiosensitivity, with excellent outcomes following conventionally fractionated radiotherapy (CFRT) or hypofractionated stereotactic radiotherapy (hSRT). Despite widespread clinical adoption of both approaches, direct comparative data assessing local control (LC) remain limited. This study aims to evaluate the relative efficacy of CFRT and hSRT to better inform optimal regimen selection for patients with Grade I meningioma.

Methods: We conducted a retrospective review of patients with Grade I meningiomas treated with RT at Thomas Jefferson University Hospital. Eligible patients received CFRT (2015 - 2025) or hSRT (2013 - 2022). Kaplan-Meier estimates were generated for LC and recurrence-free survival. Predictors for recurrence were identified using Cox proportional hazards modeling. Associations were evaluated between LC and Ki-67 index, age, and prior surgical resection for the CFRT cohort.

Results: Ninety-one (49.7%) patients received CFRT, and 92 (50.3%) received hSRT (n = 183). A median follow-up for CFRT and hSRT was 58.9 months and 28.0 months, respectively. CFRT LC rates for one, three, and five-years were 98.9%, 98.9%, and 89.9%. Corresponding LC rates for hSRT were 97.8%, 92.9%, and 87.3%. In the CFRT cohort, Ki-67, age, and prior surgery did not show significance (p < 0.05)

Conclusion: Both CFRT and hSRT achieved high and comparable local control and recurrence rates in patients with WHO Grade I meningiomas. Thus, these results indicate hSRT delivers comparable disease stabilization to conventional fractionation while offering a substantially shorter treatment course.

Additional Files
Ikea-Mario_Toren_poster.pdf (697 kB)

Language

English

Download

Share

COinS